Bergenbio Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With STK11 Mutations

Press/Media

Period	9 Mar 2023

Media coverage

Title	Bergenbio Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With STK11 Mutations
Media name/outlet	MENAFN -Press Releases (English)
Country/Territory	Jordan
Date	9/03/23
URL	ct.moreover.com/?a=50544666424&p=1gw&v=1&x=4NueMtRKsPfLp-1w013woQ
Persons	Rajwanth Veluswamy